RBM39 Contributes to MGMT Maintenance in Response to Temozolomide-Induced DNA Damage

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Resistance to alkylating agents like temozolomide (TMZ) is a major hurdle in treating MGMT-expressing tumors.
• MGMT protein expression is a key factor driving this resistance.
• RNA-binding motif protein 39 (RBM39) has been observed to associate with MGMT.

Purpose of the Study:

• To investigate the impact of RBM39 downregulation on MGMT protein levels.
• To explore the therapeutic potential of targeting RBM39 and MGMT in combination.

Main Methods:

• Pharmacological depletion and siRNA-mediated knockdown of RBM39 in cancer cells.
• Assessment of MGMT protein levels.
• Combination therapy studies involving indisulam (RBM39 inhibitor) and O6-benzylguanine (MGMT inhibitor).
• Evaluation of apoptosis and clonogenic growth in neuroendocrine tumor cells.

Main Results:

• RBM39 depletion significantly reduced MGMT protein levels in MGMT-expressing cancer cells.
• Dual targeting of RBM39 and MGMT synergistically enhanced MGMT depletion.
• Combined indisulam and TMZ treatment increased apoptosis and decreased clonogenic growth in neuroendocrine tumor cells.

Conclusions:

• MGMT is identified as a downstream target of RBM39 in MGMT-expressing cancer cells.
• Co-targeting RBM39 and MGMT presents a promising strategy to overcome resistance to alkylating chemotherapy.
• This approach holds potential for treating glioblastoma and neuroendocrine neoplasms.